The US Food and Drug Administration is working with a French drugmaker to temporarily allow imports of a medication that treats syphilis amid an ongoing shortage of the front-line treatment.

French drugmaker Laboratoires Delbert says in a letter that it’s working with the FDA to temporarily import 3.5 million units of Extencilline, which is not approved in the US. The move was approved Wednesday, according to an update on the agency’s website.

It’s similar to Bicillin, a long-acting injectable form of the antibiotic penicillin made by Pfizer that has been in short supply since the middle of last year. It’s the recommended treatment for syphilis in adults and one of a range of options to use against the infection in children. However, it’s the only recommended treatment for pregnant women, and it can prevent congenital syphilis, in which the infection passes from mother to newborn.